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Diabetes and cancer are two of the most prevalent chronic diseases today. Both of these 
conditions have implications for metabolism and nutrition management in patients affected. In 
addition, both of these conditions can be managed or improved via nutrition treatment. What is 
more difficult is patients who have both conditions as comorbidities. This scenario is common, 
as cancer increases the risk for diabetes, and vice versa. Additionally, evidence has shown that 
having both conditions as comorbidities increases the risk of mortality. This narrative review 
aims to investigate the existing evidence on nutrition management in patients with comorbid 
cancer and diabetes. Findings indicate that glycemic control is a major outcome of concern, as 
well as that self-management diabetes behaviors may be decreased in this patient population. 
Overall, the findings from this review were limited due to a lack of research into this patient 
population. Future research on glycemic control or diet adherence and cancer outcomes, as well 





Diabetes and cancer are among the most prevalent chronic conditions in the United States. In 
2015, 12.2% of all U.S. adults and 25% of those over the age of 65 had diabetes1, while 
approximately 38.4% of Americans will be diagnosed with cancer in their lifetime2. With an 
aging population and cancer and diabetes prevalence both increasing, the number of adults with 
comorbid diabetes mellitus and any type of cancer can be estimated to be anywhere between 8 – 
18% of cancer patients3.  This figure is likely to continue to increase as development of patients 
with diabetes are at increased risk of developing cancer. Diabetes has been shown to increase 
risk of kidney and colorectal cancer in all adults, breast and endometrial cancer in women, and 
pancreatic, biliary tract, and esophageal cancer in men4. Furthermore, patients with diabetes have 
greater cancer mortality compared to cancer patients without diabetes5. Conversely, the 
development of cancer may in turn increase the risk of developing diabetes, particularly in the 
cases of pancreatic and breast cancers6. 
Treatment of patients with comorbid cancer and diabetes mellitus can prove complicated as 
the treatment protocol for one condition may exacerbate the other. For instance, glucocorticoids 
used in treatment of many types of cancer are associated with impaired pancreatic beta cell 
function and hyperglycemia7. Additionally, chemotherapy can interfere with nutrition 
management of diabetes by inducing anorexia, nausea, and vomiting all of which can increase 
the risk of hypoglycemia8. However, while complicated, management of patients with both 
diabetes and cancer is of paramount importance as prognosis for this patient population is worse 
than for patients with either diabetes or cancer alone9. The risk of all-cause mortality for patients 
with comorbid diabetes and cancer has been demonstrated to be higher than for patients with 
cancer without preexisting diabetes mellitus10. Furthermore, increased risk of hypo- or 
hyperglycemia can negatively impact quality of life in this patient population11,12.  
While much research exists on diabetes and cancer independently, the body of research on 
the interplay between these two conditions is still growing. To date, the majority of research on 
these two conditions as comorbidities focuses on the association between the two, such as the 
heightened risk of developing cancer in patients with diabetes13. Some of the growing body of 
evidence also looks at possible mechanisms explaining this association14. For instance, some 
studies have observed an increased risk of cancer in patients utilizing insulin treatment 
(particularly Glargine)15. And just as glucocorticoid treatment in cancer patients can make 
glucose control more difficult for patients with preexisting diabetes, use of glucocorticoid in 
cancer treatment has been observed to increase diabetes risk in patients without preexisting 
diabetes16. This risk extends beyond cancer treatment into cancer survivorship as well. An 
increased risk of diabetes has been observed for up to 13 years after cancer diagnosis, but is 
highest in the first 2 years after diagnosis17. The metabolic adaptations caused by tumors have 
also been proposed as possible mechanisms explaining the association between diabetes and 
cancer, in addition to some of the most common forms of cancer treatment. 
 The literature also generally explores clinical treatment recommendations for patients 
with comorbid diabetes and cancer18192021. However, in general these treatment recommendations 
focus on medical interventions such as the use of insulin22 or the use of metformin to treat both 
diabetes and cancer23. Little research has been done to investigate the role of nutrition treatment 
or medical nutrition therapy in treating this patient population. Nutrition treatment is an 
important factor in both conditions. A systematic review of nutrition therapy in diabetes 
treatment suggested that nutrition therapy can reduce HbA1c 0.3%-1.6% after 6 months of 
treatment, a reduction in HbA1c similar to that found in treatment via oral-glucose lowering 
medications24. Dietary patterns have also been observed to have an impact not only on cancer 
incidence, but in mortality in cancer survivors. For example, diets high in vegetables and fish 
were associated with lower risk of mortality, and diets high in alcohol were associated with 
higher risk of mortality25. 
Thus, the objective of this narrative review is to describe nutrition interventions that have 
been evaluated in this patient population as well as this patient population’s ability to perform 
self-management behaviors, such as eating, drinking, monitoring blood glucose, and following 






Electronic searches of PubMed and SCOPUS were performed on September 20, 2018 
with no limits on publication date. An initial search of PubMed used the search terms “nutrition” 
AND “cancer” AND “diabetes.” Subsequent searches of PubMed used the search terms “enteral” 
AND “cancer” AND “diabetes” as well as “parenteral” AND “cancer” AND “diabetes.”  A 
second search of SCOPUS using the search terms “Nutrition OR diet OR dietary OR nutritional” 
AND 
“Cancer OR oncology OR neoplasm OR tumor” AND “Diabetes” AND “Intervention OR 
management OR care OR treatment OR co-managing OR co-management.” These search terms 
were used to focus the search on nutrition interventions versus non-nutrition interventions such 
as use of insulin or oral hypoglycemic agent therapies. These searches were limited to clinical 
trials and reviews. Finally, reference lists from relevant reviews were screened for other articles 
to include.   
From the initial list of titles generated in the search, duplicates were removed and then 
titles were screened to eliminate irrelevant studies. Then the abstracts were reviewed to eliminate 
non-peer reviewed articles, and articles that looked at only diabetes or cancer but not both. The 
remaining abstracts were reviewed for inclusion according to the criteria outlined below. 
Inclusion/exclusion criteria 
To be eligible for inclusion, articles met the following criteria: written in English, peer-reviewed, 
include only adults as study participants, included study participants with comorbid cancer (of 
any type) and diabetes, considered the use of nutrition treatment as opposed to non-nutrition 
treatment such as medication, and the full-text article was available.  
Data extraction 
The first author reviewed each article and extracted the following characteristics: study 
design, study duration, sample size, mean age, male/female ratio, stage of cancer, type of cancer, 
and outcome measures.  
Results 
 
The first author conducted the initial search, yielding 1,014 articles. After removing duplicates, 
996 articles remained. The remaining articles were screened by title after which 53 articles 
remained. The abstracts were reviewed for inclusion/exclusion criteria (language, intervention 
studied is specific to nutrition, etc.) after which point 30 articles remained. The remaining 30 
articles were assessed for eligibility for inclusion in this study. Additionally, 3 articles were 
found from citations in other systematic reviews; the full text of these 3 articles were also 






















Articles found in reference 
section of other articles: 3 
  




  Titles Screened: 996 





Eligible Articles Included: 
11 
  
18 duplicates removed 
Articles excluded based 
on title 
n = 943 
Full-text articles excluded: 
Articles not in English n=9 
Articles looking at non-nutrition 
interventions n = 9 
Article not available n=1 
  
Articles excluded base on abstract: 
Non-peer-reviewed articles n=1 
Articles not evaluating patients with 
simultaneous diabetes and cancer 
n = 22 
           
 
Study Characteristics 
The included studies and their characteristics are included in Table 1. The studies 
included were published between 2004 and 2018 with the most recently published article dating 
from May 2018. In the included studies, sample sizes ranged from 42 to 426,129 participants. 
This wide variation in sample size is due to the wide variety in study designs included.  
 Of the studies included, a variety of study designs were represented, including: one 
retrospective case note audit, three retrospective cohort studies, one cross-sectional observational 
study, two prospective cohort studies, and four clinical trials, two of which were randomized 
clinical trials and two of which were quasi-experimental (including one evaluation of a proposed 
a public health intervention). 
Exposures 
 The studies included in this review evaluated nutrition and self-management in patients 
with cancer and diabetes using a variety of exposures. One of the more common exposures was a 
cancer diagnosis in patients with diabetes, compared to a control of patients with diabetes but not 
cancer. One retrospective observational study measured presence of cancer compared to patients 
with diabetes and no cancer, as well as patients with diabetes and cancer and another chronic 
condition. Other studies evaluating a cancer diagnosis as an exposure variable include one 
retrospective observational study, and a cross-sectional observational study. Another 
retrospective observational study reversed this directionality by using a diabetes diagnosis as the 
exposure variable in patients with cancer. Other exposures relate to diabetes, either measuring 
the method of diabetes treatment (insulin, medication, or diet-controlled) as found in the same 
retrospective observational study that used pre-existing diabetes as a primary exposure. Along 
the same lines of treatment type, the two randomized control trials in this review evaluated 
exposures including glycemic control method during total parenteral nutrition, and use of total 
parenteral nutrition versus enteral nutrition.  
 Two prospective cohort studies explored the role of mental health in this patient 
population. One directly measured post-traumatic stress symptoms in cancer survivors as an 
exposure. The other measured self-reported symptom severity in patients undergoing 
chemotherapy and used that as the exposure to measure the association with ability to perform 
self-management behaviors. 
 Two quasi-experimental studies were also included. One evaluated tumor patients on 
TPN and compared blood glucose fluctuations in response to TPN using diabetes diagnosis as an 
exposure as well as tumor type. The second quasi-experimental study was an evaluation of a 
public health intervention design. The primary exposure was enrollment in the 4-week or 12-
week version of the group class intervention. 
Outcomes 
Glycemic control: Seven studies used glycemic control and/or hyper- or hypo-glycemic 
events as an outcome measure as a means of assessing cancer’s impact on diabetes management 
or diabetes outcomes26 27 28 29 30 31 32. Studies defined glycemic control differently. Most defined 
it as a set range of blood sugar or the amount of fluctuation in blood sugar, however HbA1C was 
also used to define glycemic control in one study33. In one case, escalation of T2D treatment was 
used as a proxy for glycemic control, evaluating if a patient escalated from diet control to oral 
hypoglycemic agents, or from oral hypoglycemic agents to insulin therapy34.  A retrospective 
case note audit looked at the chart notes for 42 patients from one hospital who had died from 
cancer and also had a diagnosis of diabetes 35, 16 out of 42 patients included reduced or 
discontinued blood glucose monitoring altogether. In this same study, two patients experienced 
hypoglycemic episodes and six experienced hyperglycemic episodes including one instance each 
of diabetic ketoacidosis and diabetic coma. 
 In an observational cohort-based study, cancer survivors with diabetes demonstrated poorer 
glycemic control versus non-cancer survivors with diabetes (31.7% and 34.6% achieving 
adequate glycemic control) however this difference was not significant. The difference between 
both these groups and non-cancer non-chronic disease participants was significant, however, 
with only 17.8% of diabetic patients without cancer or another chronic disease demonstrating 
adequate glycemic control36 .  
 A retrospective observational study evaluating men with prostate cancer measured 
glycemic control indirectly by looking at escalations in treatment for T2D. This study found men 
with prostate cancer had 1.75 times the risk of experiencing two consecutive escalations in 
diabetes treatment versus men without prostate cancer, suggesting prostate cancer may worsen 
glycemic control37.  
Conversely, one observational study using Korea National Health and Nutrition 
Examination Survey data showed higher diabetes mellitus control in specific types of cancer. 
Patients with hepatic, thyroid, and gastric cancers demonstrated 5.50, 10.73, and 16.57 times the 
odds, respectively, of demonstrating adequate glycemic control compared to other forms of 
cancer. Compared to non-cancer survivors, cancer survivors of all types were somewhat less 
likely to achieve adequate glycemic control with only 22.42% of cancer survivors included in the 
study achieving glycemic control compared to 26.13% of non-cancer survivors38 .  
From a clinical perspective, a randomized controlled trial suggested that total parenteral 
nutrition (“TPN”) was associated with more post-surgical complications and greater fluctuations 
in blood glucose versus enteral nutrition (“EN”) in patients with diabetes and gastric cancer post-
gastrectomy39.  
Another RCT found that in patients receiving enteral nutrition perioperatively, an intensive 
glycemic control strategy (versus a conventional strategy) resulted in fewer complications from 
surgery and higher likelihood of achieving blood glucose targets40. 
Similarly, in a retrospective case-control clinical trial, TPN resulted in higher blood glucose 
values in patients with diabetes versus patients without diabetes within 24 hours of TPN (12.10 
and 10.36 mmol/L, respectively) and after 24 hours of TPN (11.01 and 8.36 mmol/L, 
respectively). This same study also found that in patients with diabetes, certain types of tumors 
seem to respond with highest variations in blood glucose such as hepatic carcinomas and 
duodenal carcinomas41.  
Chronic Disease Self-Management Behaviors: Other studies evaluated the impact of chronic 
disease on self-management behaviors. Two studies used monitoring blood sugar and taking 
medication as measures of performing self-management behaviors 42 43. And one study looked at 
awareness of having diabetes as a secondary outcome in addition to treatment and control for 
diabetes44. Others looked at adherence to a Diabetes Mellitus diet45 46—although this diet was 
not defined in the literature—or referral to a dietitian47. One evaluation of a public health 
intervention measured indicators of self-efficacy and health beliefs to measure ability to perform 
self-management behaviors in the future using a Likert-scale questionnaire48. One retrospective 
observational study evaluated cancer survivors’ awareness, treatment, and control of their 
diabetes compared to two different non-cancer control groups49. This study showed that while 
they demonstrated poorer glycemic control (see previous section), 79.63% of cancer survivors 
demonstrated awareness of having diabetes versus 69.38% of non-cancer controls. This same 
study also evaluated prevalence of treatment of diabetes (defined as use of medical treatment 
such as insulin or oral hypoglycemic agents) and found 72.22% of cancer survivors reported 
treatment of diabetes versus 63.23% of non-cancer survivors.  
A prospective observational study examined participants’ (n = 44) use of diabetes self-
management behaviors before and after 8 weeks of chemotherapy, showing that self-
management behaviors were significantly decreased after just 8 weeks of treatment, with ability 
to eat and drink being one of the most affected self-management behaviors along with blood 
sugar monitoring. This decrease in self-management behaviors coincided with a simultaneous 
reported increase in symptom burden from cancer treatment. This study also contained a 
qualitative component in which patients undergoing cancer treatment provided feedback on 
managing diabetes. Some observations pulled from this data included patients noting that 
diabetes management became less of a priority for them during cancer treatment, sometimes 
under the guidance of their medical provider. Patients also reported decreased ability to perform 
self-management behaviors such as exercise, diet, taking medication, and monitoring blood 
sugar50.  
In this same vein, one prospective cohort study of cancer survivors’ (n = 56) use of diabetes 
self-management behaviors showed that cancer survivors with higher post-traumatic stress 
symptoms were 0.08 times as likely to adhere to the recommended diet for diabetes mellitus51. In 
a retrospective case note audit of patients with advanced cancer and diabetes, it was observed 
that six out of 42 patients with comorbid cancer and diabetes were referred to a dietitian and 
seven out of 42 used diet interventions to manage diabetes mellitus versus medical intervention 
such as use of oral hypoglycemic agents or insulin in an inpatient setting52. Finally, the last study 
investigating self-management behaviors in this population evaluated self-management 
behaviors before and after implementation of a group-focused public health intervention in the 
form of weekly group nutrition and physical activity classes designed for cancer survivors. 
According to this study, a well-planned, culturally appropriate public health intervention can 
increase cancer survivors’ self-efficacy in adhering to a DM management diet, among other self-
management behaviors. Participants in the 12 week session of the intervention showed 
significant improvements in mean waist circumferences compared to participants in the 4 week 
intervention; and across interventions, over 90% participants reported the intervention motivated 
them to engage in healthy behaviors and that the nutrition education sessions were relevant to 
them.  
Cancer outcomes: One retrospective observational study evaluated the impact of various 
types of diabetes mellitus treatment strategies and mortality in patients with comorbid cancer and 
diabetes (n = 426,129. According to this study, the non-medical intervention (ie management via 
diet) was associated with lowest mortality rates in this patient population. Men with diabetes and 
cancer not receiving OHA or insulin treatment had 1.10 times the risk for mortality compared to 
cancer patients without diabetes. The hazard ratios for patients with diabetes undergoing OHA 
treatment and insulin treatment were 1.23 and 1.49, in comparison53. It is worth noting, however, 
this association may be due to treatment via OHA or insulin reflecting a further progression of 
diabetes rather than being a causal factor for mortality. 
 
         Discussion 
This review aimed to evaluate the current body of evidence surrounding nutrition care in 
patients with comorbid diabetes and cancer. Little research has been done on specific nutrition 
interventions in this patient population. The research that currently exists has established a 
poorer prognosis in this patient population versus patients with just one chronic condition, as 
well as higher risk of developing the other condition once diagnosed with either. The prevalence 
of coexisting cancer and diabetes is expected to grow, and management of patients with both 
conditions warrants unique considerations.  The presence of cancer can worsen a patient’s ability 
to manage their diabetes due to both the metabolic adaptations present in cancer and also due to 
the mental health effects of a cancer diagnosis and subsequent cancer treatment. This leads to a 
cycle in which a patient has more difficulty caring for one condition which then exacerbates the 
other condition. The findings from this review on the impact of cancer on glycemic control are 
inconclusive, but there is some suggestion that glycemic control may be poorer in patients with 
cancer. Further research is needed in this area.  
Additionally, the findings from this review suggest that while nutrition support may be 
necessary in advanced stages of cancer, careful consideration must be taken when choosing a 
method of nutrition support as certain forms such as TPN can worsen glycemic control leading to 
both hyper- and hypoglycemic episodes. Dietitians in a clinical setting would do well to 
prioritize oral feeding for as long as possible, keeping in mind traditional nutrition strategies for 
glycemic control. Once that is no longer an option, a possible best practice would be to use as 
much of the gastrointestinal tract as possible, leaving TPN as the last resort to prevent protein 
energy malnutrition.  
One of the most interesting findings from this review is the connection between mental 
health, cancer survivorship, and ability to self-manage diabetes. This review demonstrated that 
cancer treatment has negative impacts on self-management behaviors in patients with diabetes, 
and that these effects are higher in patients with higher levels of post-traumatic stress symptoms. 
Furthermore, these effects last beyond cancer treatment and extend into cancer survivorship. This 
connection suggests one of the key variables in the association between poor glycemic control 
and cancer mortality is mental health. What is promising, however, is the suggestion that this 
population can experience increased self-efficacy in managing diabetes through well-planned 
public health interventions. Clinicians treating patients with comorbid diabetes and cancer can 
address this by referring patients to mental health treatment and emphasizing the importance of 
continued diabetes self-management, and connecting patients to resources for assistance. Long-
term, including mental health care in the coordinated care plan of patients with diabetes and 
cancer alongside oncology, endocrinology, and nutrition may be beneficial.  
 While some trends and recommendations can be drawn from this review, the findings of 
this review were somewhat limited by the narrow scope of research in this area. There are few 
clinical trials assessing different feeding methods or diet interventions in this patient population. 
Additionally, the clinical trials that do exist are limited by small sample sizes. The wide variation 
in sample size across studies included leads to some difficulty in making comparisons. However, 
this is due to the variation in types of studies included. By its nature, an observational study 
using publicly available survey data will have a much wider sample size than an intervention 
which requires participants to actively participate in the study.  
 Several of the studies investigated this patient population’s ability to maintain a diabetes-
friendly diet, however, none of the studies included defined this eating pattern so it is difficult to 
draw comparisons. Future investigators may wish to look into defining a set diabetes-diet and 
looking at an association between adherence to this diet and cancer outcomes.   
 This review does carry several strengths. Most research has looked at the impact of 
cancer or the impact of diabetes but few studies have looked at the impact of both conditions 
simultaneously. This is a new area of study, and one that has real clinical implications as the 
patient population with both conditions is large.  Finally, the systematic search method used in 
this review is an advantage.  
Because of the importance of nutrition in managing diabetes, and the importance of 
maintaining glycemic control to improve cancer outcomes in this patient population, further 
research into how to improve nutrition care in this population is warranted. Within this patient 
population, research should be done investigating the level of glycemic control and mortality risk 
in patients with diabetes and cancer, as well as how specific diet interventions or feeding 
methods affect cancer outcomes and/or mortality in this population. Finally, further research on 
mental health interventions or treatment and mortality risk is needed.  
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